L'Agence nationale de la recherche Des projets pour la science

Investissements d'avenirProjets financés

Un module intégré de phénotypage permettant le suivi des réponses immunitaires anti-infectieuses (PHENOMIX)

Action : Equipements d'excellence

N° de convention : 10-EQPX-0011

Informations générales

  • Référence projet : 10-EQPX-0011
  • RST : Bernard MALISSEN
  • Etablissement Coordinateur : INSERM Marseille
  • Région du projet : Provence-Alpes-Côte d'Azur
  • Discipline : 5 - Bio Med
  • Aide allouée : 1 499 140 €
  • Date de début du projet : 22/02/2011
  • Date de fin du projet : 31/12/2019
  • Site web du projet : http://ciphe.marseille.inserm.fr/
  • Mots clés : immunity; infection; immunophenotyping; flow cytometry; imaging

Résumé du projet

The Center for Immunophenomics (CIPHE) is a service provider unit that operates under the administrative authority of INSERM (INSERM US12), CNRS and AMU (UMS3367). As a technological platform, CIPHE participates to research programs at the national and european levels (ERC, ANR, INCA, ARSEP) and PIA (Programme Investissements d’Avenir) such as PHENOMIN, PHENOMIX, DC-BIOL, MIMab that focus primarily on Immunology, Infection and Cancer. In that frame, the EQUIPEX program PHENOMIX was specifically intended to develop novel services allowing us to pioneer multiparametric standardized immunophenotyping of mutant mice following infections with pathogenic microbes. Owing to the many regulatory issues to be fixed and standard operating procedure to be established, the CIPHE BSL3 module became fully operational in 2015. The BSL3 platform within CIPHE has been evaluated positively by the ANSM and HCB committees in 2015, allowing the importation, manipulation and storage of pathogenic agents of the "Group 1, Annex 2".  The authorizations were delivered - 02/12/2014, 23/04/2015 and 02/10/2015 by the ANSM and on - 27/02/2015 and 25/09/2015 for GMO. It is intended to challenge the immune system of normal and mutant mice with pathogens and to analyze immune parameters of biological samples of interest at various time of infection using advanced flow cytometry and microscopy techniques. Importantly, the CIPHE BSL3 also permits to test the impact of vaccines and adjuvant on anti-microbial immune responses. The resources allocated via the PHENOMIX project permitted us to acquire during Phase 1 (2011-2013) a Fortessa BD cytometer, a BD cytometer with 3 lasers and 8 colors (FACS Verse), a luminometer Magpix and a TCS SP5 laser scanning microscope. These equipments have been acquired according to the original initial Phase I schedule. The budget allocated for Phase II (2014-2019) contributes to the operational maintenance of the suite of instruments funded by PHENOMIX.    

(L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.)